Spots Global Cancer Trial Database for total body irradiation
Every month we try and update this database with for total body irradiation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | NCT01810588 | Hematologic Mal... | CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus | 18 Years - | Weill Medical College of Cornell University | |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | NCT00303719 | Kidney Cancer Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... cyclosporine fludarabine mycophenolate m... stem cell trans... total body irra... filgrastim | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies | NCT01622556 | Hematologic Mal... | Fludarabine Busulfan Thymoglobulin Total Body Irra... Umbilical Cord ... | 18 Years - 70 Years | University of Virginia | |
| BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT | NCT02670252 | Allogeneic Hema... Busulfan Total Body Irra... Acute Lymphocyt... | Busulfan (BU) Cyclophosphamid... Total Body Irra... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer | NCT00376805 | Breast Cancer | Fludarabine Cyclophosphamid... Total body irra... Natural killer ... Interleukin-2 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia | NCT03408223 | Acute Leukemia | total body irra... total marrow an... | 8 Years - 65 Years | Affiliated Hospital to Academy of Military Medical Sciences | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation | NCT03159702 | Hematological M... Multiple Myelom... | Evomela Fludarabine Total Body Irra... | 18 Years - | Medical College of Wisconsin | |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation | NCT06028828 | Allogeneic Hema... Allogeneic Stem... Hematologic Mal... | Fludarabine Melphalan Total Body Irra... | 18 Years - 70 Years | University of California, Irvine | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | NCT02702960 | Fibrolamellar H... Hepatocellular ... Hepatocellular ... | living related ... Total body irra... Bone marrow tra... Cyclophosphamid... Mesna Filgrastim Tacrolimus mycophenolate m... Prednisone Antithymocyte g... fludarabine | 16 Years - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia | NCT01991457 | Adult Lymphobla... | Fludarabine Total Body Irra... | 40 Years - 65 Years | University of Alabama at Birmingham | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | NCT01119066 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Multiple Myelom... | total body irra... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine Clofarabine (CliniMACS) T-c... | - 69 Years | Memorial Sloan Kettering Cancer Center | |
| Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia | NCT00623935 | Acute Myelogeno... | Fludarabine Busulfan Total Body Irra... Stem Cell Trans... | 55 Years - 70 Years | University of Michigan Rogel Cancer Center | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | NCT00602693 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus | 18 Years - 75 Years | Masonic Cancer Center, University of Minnesota | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR | NCT02497404 | Leukemia, Eryth... Myelodysplastic... | 5-Azacytidine Fludarabine Melphalan Alemtuzumab Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL | NCT03042585 | Relapsed Non Ho... Refractory Non-... | Total body irra... | 18 Years - | Loyola University | |
| T-Cell Depleted Double UCB for Refractory AML | NCT01464359 | Acute Myelogeno... Refractory Acut... | Allopurinol Fludarabine Total body irra... Cyclophosphamid... Levetiracetam Busulfan Umbilical Cord ... Interleukin-2 | 2 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | NCT06001385 | Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis | Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid... | 18 Years - | Center for International Blood and Marrow Transplant Research | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | NCT01163201 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-... | Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ... | 18 Years - 55 Years | Masonic Cancer Center, University of Minnesota | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia | NCT00002961 | Leukemia | cyclophosphamid... cyclosporine etoposide methotrexate allogeneic bone... Total Body Irra... Busulfan Mesna Radiation | - 21 Years | Children's Hospital of Philadelphia | |
| Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia | NCT00002961 | Leukemia | cyclophosphamid... cyclosporine etoposide methotrexate allogeneic bone... Total Body Irra... Busulfan Mesna Radiation | - 21 Years | Children's Hospital of Philadelphia | |
| Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | NCT00303719 | Kidney Cancer Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | anti-thymocyte ... cyclophosphamid... cyclosporine fludarabine mycophenolate m... stem cell trans... total body irra... filgrastim | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | NCT00679536 | Leukemia | Busulfan Fludarabine Thymoglobulin Total Body Irra... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source | NCT02167958 | Leukemia MDS Myelofibrosis Lymphoma | Fludarabine Cyclophosphamid... Mesna Total Body Irra... Hematopoietic s... Tacrolimus Mycophenolate G-CSF | 18 Years - 70 Years | University of Pittsburgh | |
| Infusion of Expanded Cord Blood T Cells | NCT00972101 | Stem Cell Trans... Leukemia Lymphoma Pediatric Disor... | Total Body Irra... Melphalan Thiotepa Fludarabine Rituximab Etoposide Anti-thymocyte ... Mycophenolate M... Tacrolimus Cord Blood Infu... G-CSF Ex vivo expande... | - 55 Years | M.D. Anderson Cancer Center | |
| Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia | NCT01991457 | Adult Lymphobla... | Fludarabine Total Body Irra... | 40 Years - 65 Years | University of Alabama at Birmingham | |
| Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | NCT06337331 | Acute Myeloid L... Myelodysplastic... | Venetoclax Decitabine Fludarabine Busulfan Total Body Irra... | 18 Years - | Northside Hospital, Inc. | |
| Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI) | NCT00581958 | Cancer | Blood Samples | 4 Years - 100 Years | Memorial Sloan Kettering Cancer Center | |
| Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia | NCT00186966 | Acute Myeloid L... | Fludarabine, Cy... Etoposide, Thio... Hematopoietic s... Total body irra... | - 18 Years | Dutch Childhood Oncology Group | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT | NCT04509765 | Hematologic Mal... | Linac Based VMA... | 18 Years - | NYU Langone Health | |
| Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | NCT00679536 | Leukemia | Busulfan Fludarabine Thymoglobulin Total Body Irra... | - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | NCT01163201 | Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-... | Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ... | 18 Years - 55 Years | Masonic Cancer Center, University of Minnesota | |
| Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma | NCT00513604 | Melanoma Malignant Melan... Melanoma, Exper... Experimental Me... | aldesleukin therapeutic aut... Cyclophosphamid... Fludarabine pho... Total body irra... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors | NCT01349101 | Hematological M... | Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s... | 18 Years - | Thomas Jefferson University | |
| Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML | NCT00069992 | Chronic Myelopr... Leukemia Myelodysplastic... | Total Body Irra... Fludarabine Campath 1H | - | Baylor College of Medicine | |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | NCT03480360 | Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Myelodysplasia Myeloproliferat... Myelofibrosis Lymphoma Lymphoma, Non-H... Plasma Cell Dis... | Cyclophosphamid... Fludarabine Total Body Irra... Tacrolimus cellcept g-csf Peripheral Bloo... | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors | NCT01509300 | Acute Leukemia Myelodysplastic... Solid Tumors | anti-thymocyte ... filgrastim Total body irra... Fludarabine cyclophosphamid... Tacrolimus Mycophenolate m... Rituximab | - 21 Years | Asan Medical Center | |
| Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies | NCT01203722 | Hematologic Mal... | Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant | NCT00305682 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | anti-thymocyte ... cyclophosphamid... Fludarabine mycophenolate m... umbilical cord ... total body irra... Sirolimus | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | NCT01341301 | Hematologic Mal... | Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | NCT00382109 | B-cell Childhoo... Childhood Acute... Graft Versus Ho... L1 Childhood Ac... L2 Childhood Ac... T-cell Childhoo... | thiotepa cyclophosphamid... tacrolimus methotrexate sirolimus total body irra... | 1 Year - 21 Years | Children's Oncology Group | |
| Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | NCT00709592 | Non-Hodgkin's L... Leukemia Multiple Myelom... Acute Myeloid L... Hodgkin Lymphom... Chronic Lymphoc... Chronic Myeloge... Myelodysplastic... | Thymoglobulin Total-Body Irra... Allogeneic PBSC... Tacrolimus Mycophenolate M... | 40 Years - 70 Years | Virginia Commonwealth University | |
| T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | NCT03531736 | Myeloid Disease... | Antithymocyte g... fludarabine total body irra... cyclophosphamid... Rituxan Allogeneic Hema... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies | NCT04959175 | Hematologic Neo... | Mycophenolate M... Allogeneic HSCT Fludarabine Sirolimus Filgrastim Cyclophosphamid... Mesna Total Body Irra... | 12 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00525876 | Lymphoma | Cyclophosphamid... Fludarabine Rituximab Alemtuzumab Allogeneic Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation | NCT06110572 | Extensive Stage... Stage IV Lung C... | Carboplatin Atezolizumab Etoposide Total Body Irra... Hypofractionate... Magnetic Resona... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Radiation Biodosimetry in Patients Treated With Total Body Irradiation (TBI) | NCT00581958 | Cancer | Blood Samples | 4 Years - 100 Years | Memorial Sloan Kettering Cancer Center | |
| Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies | NCT01247688 | Lymphoid Hemato... Umbilical Cord ... | Cytoxan Fludarabine Total Body Irra... Cord Blood Stem... | - | Baylor College of Medicine | |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | NCT00303667 | Acute Myelogeno... | aldesleukin natural killer ... cyclophosphamid... fludarabine pho... allogeneic hema... total body irra... Thymoglobulin Cyclosporin A cyclophosphamid... fludarabine pho... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | NCT06175702 | Lymphoblastic L... Philadelphia-Po... Adult ALL | Vincristine Dexamethasone Imatinib Cytarabine Mercaptopurine Methotrexate Ponatinib allogeneic stem... Total body irra... Cyclophosphamid... Fludarabine | 18 Years - | PETHEMA Foundation | |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | NCT04904588 | Acute Lymphobla... Acute Myelogeno... Mixed Phenotype... Acute Leukemia Myelodysplastic... Chronic Myeloge... Chronic Lymphoc... Lymphoma | Busulfan Busulfan Fludarabine Total-body irra... Cyclophosphamid... Melphalan PBSC Hematopoie... Bone Marrow Hem... Post-transplant... Mesna Tacrolimus Mycophenolate M... Patient-Reporte... | 1 Year - | Center for International Blood and Marrow Transplant Research | |
| A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT | NCT00460421 | Leukemia | Palifermin Total Body irra... Chemotherapy | 1 Year - 16 Years | Swedish Orphan Biovitrum | |
| Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation | NCT00328237 | Acute Myeloid L... Acute Lymphobla... Chronic Myeloid... Non-Hodgkin Lym... Myelodysplastic... | Cord Blood Tran... | 18 Years - 49 Years | Colorado Blood Cancer Institute | |
| Treg Cells for AGVHD in Non-myeloablative UCB Transplant | NCT02118311 | Hematologic Mal... | T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra... | 18 Years - 69 Years | Masonic Cancer Center, University of Minnesota | |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | NCT06252870 | Graft Versus Ho... Hematologic Mal... | Methotrexate Post-Transplant... Fludarabine Cycophosphamide Anti-Thymoglobu... total body irra... hematopoietic s... Graft nuclear c... Donor Lymphocyt... Clofarabine Thiotepa Busulfan Fludarabine | 18 Years - 70 Years | Nantes University Hospital | |
| Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma | NCT00793845 | Neuroblastoma | Cyclophosphamid... Etoposide Carboplatin Thiotepa Melphalan Total body irra... | - | Samsung Medical Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | NCT02556931 | Myelodysplastic... Chronic Myelomo... Small Lymphocyt... Chronic Lymphoc... Prolymphocytic ... Chronic Myeloid... Chronic Myelopr... Multiple Myelom... Plasma Cell Neo... Plasma Cell Dys... Myelofibrosis Polycythemia Ve... Essential Throm... Plasma Cell Leu... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate m... | - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
